German Biotech Sector has developed to World Class Technology

The biotech industry in Germany reached new levels of maturity when compared to the previous years, both the number of employees and the revenues generated by the sector increased markedly. Germany is home to more biotech companies than any other country in Europe. The latest figures show nearly 500 dedicated biotechnology firms in the country, over 20 of which are listed on the stock exchange. Two out of every five dedicated biotech companies in the country have secured venture capital financing, while more than a third benefit from public grants or subsidies. R&D expenditure in 2005 exceeded 700 million euros. German biotech companies have everything you need to create value on a high quality level.” Comparing business conditions for biotech companies in Germany and the United States. Germany has significantly lower operating costs.” The panelists agreed that the cost advantages in Germany are particularly noticeable for companies involved in conducting clinical trials.

According to a noted scholar and researcher “ The biotechnology industry in German is completely undervalued “. For a scientist like Simon Moroney, hoping to swap academia for industry, moving to Germany in the early 1990s was a risky move. With strict laws hindering drug research and strong public opposition to genetic engineering, German biotechnology seemed dead before it even started. Fifteen years later and it’s not just the beer and bratwurst that entice British scientists to follow in Moroney’s footsteps, but an impressive hub of biotechnology. Germany’s biotechnology industry is actively seeking international investors to leverage opportunities in Europe’s largest biotech market. With generous public and private-sector support, cooperation is being encouraged particularly in the fields of health and medicine, industrial biotech and nano-biotechnology.

Click here to Continue Reading
​
For more updates visit HarNeedi.com